http://www.select-access.com/releases.html News and information about Select Access, a targeted sales solution for a diverse group of pharmaceutical products providing unmatched value and increasing incremental revenue for Established Brands, Ethical OTC Brands, Seasonal Brands and Specialty Brands that could gain an additional revenue stream from a primary care presence. en-us 27 Sep 2005 16:00:00 EST Copyright 2005, Select Access, a division of PDI http://www.select-access.com/feeds/select-rss-icn.gif http://www.select-access.com/releases.html This is an XML content feed. It is intended to be viewed in a newsreader or syndicated to another site, subject to copyright and fair use. http://www.select-access.com/releases/news-2005-09-27.html Saddle River, New Jersey (September 27, 2005) PDI, Inc. (NASDAQ: PDII), a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries, is pleased to announce that its Select Access business unit has made the following additions to its Executive Leadership Team 27 Sep 2005 16:00:00 EST healthcare http://www.select-access.com/releases/news-2005-07-21.html Saddle River, New Jersey (July 21, 2005). PDI, Inc. (NASDAQ PDII) a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries, today announced that it is the Platinum Sponsor of Pharmaceutical Executives Sales Summit. The Summit is being held from July 27 through July 29, at the Baltimore Marriott Waterfront in Baltimore, Maryland. 21 Jul 2005 16:00:00 EST healthcare http://www.select-access.com/releases/news-2005-07-19.html Saddle River, NJ (July 19, 2005) PDI, Inc. (NASDAQ PDII) a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries, today announced that its Select Access unit has been selected by Allergan, Inc. (NYSE AGN) to co-promote Zymar (gatifloxacin ophthalmic solution 0.3 percent), the first FDA approved fourth generation topical fluoroquinolone indicated for the treatment of bacterial conjunctivitis, to primary care practitioners. Zymar represents a recent advance in countering emerging antimicrobial resistance and is currently the No. 1 prescribed fluoroquinolone among ophthalmologists. 19 Jul 2005 16:00:00 EST healthcare http://www.select-access.com/releases/news-2005-07-07.html SADDLE RIVER, N.J. (July 7, 2005) PDI, Inc. (NASDAQ PDII), announces the introduction of Select Access, a targeted sales force solution. With a sales force of approximately 350 experienced sales professionals already in high prescribing territories, Select Access maximizes profitability for a diverse group of brands. Established prescription, OTC and specialty brands that benefit from a primary care presence are a perfect fit for Select Access. 07 Jul 2005 16:00:00 EST healthcare